Highlights
KLSE: DPHARMA (7148)       DUOPHARMA BIOTECH BHD MAIN : Health Care
Last Price Today's Change   Day's Range   Trading Volume
1.45   +0.05 (3.57%)  1.39 - 1.48  1,233,700
Trade this stock with T+7 trading account. Find out more.

Overview

Market Cap: 986 Million
NOSH: 680 Million
Avg Volume (4 weeks):589,416
4 Weeks Range:1.29 - 1.48
4 Weeks Price Volatility (%):
84.21%
52 Weeks Range:0.925 - 1.48
52 Weeks Price Volatility (%):
94.59%
Average Price Target: 1.58
Price Target Upside/Downside: +0.13
Stamp duty exempted for year 2019

Financial Highlight

Latest Quarter | Ann. Date 31-Mar-2019 [#1]  |  21-May-2019
Next QR | Est. Ann. Date: 30-Jun-2019  |  26-Nov-2019
T4Q P/E | EY: 19.16  |  5.22%
T4Q DY | Payout %: 3.11%  |  59.61%
T4Q NAPS | P/NAPS: 0.7299  |  1.99
T4Q NP Margin | ROE: 9.98%  |  10.37%

Headlines

Date Subject
23-Aug-2019 Stocks on Radar - Duopharma Biotech (7148)
08-Aug-2019 Trading Stocks - Duopharma Biotech
26-Jul-2019 [转贴] DPHARMA 清真药剂股龙头 | 股市的避风港行业 | 药剂股分析 | 雪人诊股 EP11
01-Jul-2019 Stocks on Radar - Duopharma Biotech (7148)
24-Jun-2019 [DPHARMA] AGM股东大会摘录
26-May-2019 Duopharma Biotech Berhad (KLSE) #FundamentalDaily - yapss
23-May-2019 Duopharma Biotech Berhad - Strong 1Q19 Numbers
21-May-2019 Trading Stocks - Duopharma Biotech
17-May-2019 药剂股研发金额露端倪/黄云浩
13-May-2019 Trading Stocks - Duopharma Biotech
24-Apr-2019 Stocks on Radar - Duopharma Biotech (7148)
11-Apr-2019 联合药业挑战RM1.45/敏源
29-Mar-2019 Trading Stocks - Duopharma Biotech
22-Mar-2019 Trading Stocks - Duopharma Biotech
22-Mar-2019 Stocks on Radar - Duopharma Biotech (7148)
22-Mar-2019 Duopharma Biotech Berhad - Expecting FY19 to be a Stronger Year
20-Mar-2019 Trading Stocks - Duopharma Biotech
19-Mar-2019 Daily Market Update - 19 Mar 2019 (CYPARK, DPHARMA)
12-Mar-2019 联合药业 有望赢取新合约
08-Mar-2019 Duopharma Biotech Berhad - EPO and Oncology the Growth Engines

Business Background

Duopharma Biotech Berhad, an investment holding company, manufactures, distributes, and imports pharmaceutical products and medicines in Malaysia. The company provides products in various forms, including tablets, capsules, syrups, oral antibiotics, creams, hemodialysis solutions, sterile irrigation solutions, sterile powder and small volume injectable forms, dental cartridges, and eye drop preparations. It offers generic and halal pharmaceutical products; and over-the-counter products primarily under the Champs, Flavettes, Proviton, Naturalle, Uphamol, Eye Glo, Donna, and Alucid brands, as well as analgesics, antihistamines, etc. The company also operates under the OMESEC brand name. In addition, it is also involved in the property management activities; and distribution of chemical products. Duopharma Biotech Berhad also exports its products to Vietnam, Ethiopia, Sudan, Southeast Asia, Papua New Guinea, Pakistan, Bangladesh, Sri Lanka, the Republic of Yemen, Singapore, and Hong Kong. The company was formerly known as CCM Duopharma Biotech Berhad and changed its name to Duopharma Biotech Berhad in February 2019. The company was founded in 1979 and is based in Klang, Malaysia. Duopharma Biotech Berhad is a subsidiary of Permodalan Nasional Berhad.
Analyze this stock with MQ Trader system

  4 people like this.
 
factorrumour congrats to all shareholders, a new beginning awaits you all

duopharma biotech!
25/02/2019 10:51 PM
cmshyong when is the ex date for 4 sen dividen?
26/02/2019 7:35 PM
catchcon factorrumour congrats to all shareholders, a new beginning awaits you all

duopharma biotech!

It's good brother, better things to come.
11/03/2019 5:13 AM
chshzhd @factorrumour div for fy17 was 3.6sen bcos the adjustment of bonus issue at june last year
12/03/2019 11:43 AM
chshzhd ..so div 5.5sen for fy18 actually is an improvement of 55% !
12/03/2019 11:45 AM
chshzhd @cmshyong the ex date for 4 sen will be around june this year.
12/03/2019 11:46 AM
Chengkai Kok 目标价:1.52令吉
最新进展:

联合药业(DPHARMA,7148,主板保健股)持续预见大马公共和私人保健领域需求强劲,归功政府增加卫生部拨款。

联合药业去年的销售量仍是大马领先业者;而以销售值来看,从第三名攀升至第二名。

该公司近期取得相关机构批准,出售红血球生成素(EPO)生物仿制药,同时肿瘤设备料于今年第三季推介。

在大马,肿瘤科产品市值高达4亿令吉,所以该利基产品有巨大的机会。

目前本地还未有肿瘤科的设备,该公司计划推出2至3种主要产品来夺得25%市占率(1亿令吉)。

行家建议:

我们预计,联合药业可赢得新的EPO合约、及更新胰岛素合约,并保住市场领导地位。

我国的EPO市场市值达5000万令吉至6000万令吉间,相信该公司有能力与其他供应商竞争,争夺政府大约介于1000万令吉至1500万令吉的合约。

针对今年到期的胰岛素合约,相信该公司可凭借更便宜的价格,延长现有合约2年;若失败,将冲击下财年盈利预测7%。
12/03/2019 1:26 PM
keyin Why no movement,boring
16/03/2019 12:16 PM
Manekineko Hahaha, healthcare counter is like that la... Slow but steady...
18/03/2019 12:32 PM
Dakewlest Moving up. Any TP, anyone?
21/03/2019 6:49 PM
keyin Tp3
21/03/2019 7:15 PM
kmwong8711 For me above 1.30 is good
21/03/2019 7:59 PM
k3nthiew go! go! go!
22/03/2019 9:05 AM
k3nthiew Getting contract soon?
22/03/2019 9:05 AM
Investeye TA Research - 22 Mar 2019 Valuation & Recommendation :
We maintain Buy on Duopharma with a higher TP of RM1.61/share (previously RM1.52/share) based on unchanged 20.0x CY19 PER. We continue to like Duopharma for its: i) strong market share in Malaysia, and ii) move into niche pharmaceuticals products.
22/03/2019 9:41 AM
yapchehhak https://www.theedgemarkets.com/article/insulin-epo-new-products-expected-boost-duopharma-fy19-earnings
26/03/2019 1:05 AM
k3nthiew Push harder please....
28/03/2019 4:20 PM
yapchehhak Slow and steady win the race
29/03/2019 7:31 AM
chshzhd good counter,keep for long term..
29/03/2019 12:35 PM
Manekineko Agree, waiting for next entry point when drop.
03/04/2019 4:38 PM
Dakewlest Any idea for next entry point?
04/04/2019 10:30 AM
Dakewlest Anyone know when are we getting the 4sen dividend?
08/04/2019 10:34 AM
chshzhd last year div ex june
08/04/2019 11:05 AM
VSOLAR Sailang Margin All In Punter thinking this counter not bad too
08/04/2019 9:35 PM
Dakewlest I bought some this week... may add some more later.
10/04/2019 3:50 PM
Investeye Disposed some to take profit..
10/04/2019 4:54 PM
Investeye Disposed most of the lots as EPF is gradually disposed this counter..
Wait for next wave..
23/04/2019 9:56 AM
Dakewlest Epf acquired last week.
23/04/2019 12:28 PM
Investeye Disposed all DPharma and bank on Pharma. In general, EPF disposed more than acquired..
23/04/2019 4:40 PM
keyin Why EPF do so
23/04/2019 5:37 PM
VinLol123 This counter suitable for long term..
27/04/2019 3:31 PM
YAPSS Day 81 of Fundamental Daily, YAPSS will be covering Duopharma Biotech Berhad's fundamental via a short animated video. I hope it helps and please enjoy the video, see ya! #YAPSS #FundamentalDaily #DuopharmaBiotechBerhad

Click the on the link to find out more: https://youtu.be/wKtLhzvZy_c
25/05/2019 9:28 AM
moneytrail Going for DRP and hold long term! Healthy sales!
22/06/2019 6:39 PM
factorrumour price has been flat for quite some time already, is it a good time to enter?
25/06/2019 4:08 PM
Ern Siah How to do the reinvestment?
26/06/2019 12:41 AM
NewbieTradingChannel Dpharma 7/7/2019 now it is on a symmetrical triangle ... breaking 1.3900 can target 1.440.
07/07/2019 1:25 PM
Jason bullish engulfing with volume, show time?
01/08/2019 4:22 PM
k3nthiew https://www.reuters.com/article/us-duopharma-btech-malaysia/malaysias-duopharma-talks-deals-with-trade-war-hit-chinese-firms-idUSKCN1UW0E4
06/08/2019 4:11 PM
k3nthiew KUALA LUMPUR (Reuters) - Duopharma Biotech (DUOP.KL), Malaysia’s largest generic drugmaker, is in talks with two Chinese consumer healthcare companies for expansion of their production base in Southeast Asia and a potential stake sale, its managing director said.

During an interview with Reuters, Duopharma Managing Director Leonard Ariff bin Abdul Shatar declined to name the companies as the discussions were ongoing. However, he said both “reasonably big” companies were listed in China with an annual revenue of more than $1 billion each.

The Chinese companies, one based in Shanghai and the other in Beijing, had asked Kuala Lumpur’s Duopharma if it would be able to contract-manufacture for them. They have also discussed buying a stake in Duopharma, Leonard said.

“They have manufacturing bases currently in China, supplying to the United States. These are guys whom I would not have expected to see in this part of the world, but for the trade war,” he said.

Duopharma, which has a market valuation of about $220 million, was open to a stake sale of up to 10% in the company, Leonard said, adding that if a deal was finalised, the Malaysian firm will apply to register with the U.S. Food and Drug Administration.

“There is a famous Malay saying: when two elephants fight, the ants die. But what we see here is absolutely the opposite. This has come as a bit of a surprise,” he said.

Dented by higher U.S. tariffs, Chinese companies are seeking partners to partly shift their supply chain to Southeast Asian countries such as Vietnam, Malaysia and Indonesia, analysts and Malaysian government officials said.

In the first quarter of 2019, Southeast Asia’s third-biggest economy attracted foreign investment of more than $7 billion – a 73% surge from a year earlier. The Malaysian government and its trade agencies are sending their representatives to China and other countries, organizing seminars and signing agreements of cooperation.

Late last month, the China ambassador to Malaysia confirmed the high level of Chinese interest in its traditional trade partner.
06/08/2019 4:12 PM
Coldman Very good news for stakeholder, hope it can be deal soon.
06/08/2019 4:50 PM
Jason Good fundamental and aggressive management. This counter is worth to hold for long term investment.
06/08/2019 5:20 PM
moneytrail No action yet. So difficult to bull doze pass 1.43. :(
07/08/2019 11:04 PM
Jason 1.43 been tested many times. Damn hard to breach.
08/08/2019 9:36 AM
Shootup what so good it is, gotta share profit out after the deal
09/08/2019 6:19 AM
Jason what happens to dpharma today?
21/08/2019 5:07 PM
kalofarmako Hello
22/08/2019 3:37 PM
Jason hope it can break the strong resistance at 1.43.
22/08/2019 4:25 PM
factorrumour only super good quarter result can help it push to all time high and new record
23/08/2019 12:07 AM
Jason finally it moves after consolidate for so long
23/08/2019 2:56 PM
Shootup All time high qr must be good
23/08/2019 3:14 PM


 

397  252  529  780 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 EKOVEST 0.845+0.04 
 IWCITY 0.95+0.08 
 GPACKET-WB 0.185+0.01 
 VSOLAR 0.1350.00 
 GPACKET 0.645+0.04 
 HSI-H6P 0.17-0.025 
 AAX 0.185-0.01 
 KNM 0.365+0.005 
 HSI-C7E 0.21+0.02 
 HSI-C7F 0.405+0.035 

TOP ARTICLES

1. ISKANDAR LANDED PROPERTIES PRICED BELOW RM450K – BEST BUY IN THE WHOLE WIDE WORLD! (Calvin Tan Blog) THE INVESTMENT APPROACH OF CALVIN TAN
2. My Top Points List 5: TAKAFUL (6139), RCECAP (9296), HAPSENG (3034) WahLau Share Forecast
3. Mi 正齐科技 5286: 上周四出了业绩,周五大热!季报有什么好料? 投资有理·于你
4. China: USA: Malaysia Economic Model “Shared Prosperity 2030” Sslee blog
5. These Countries Are the Winners of the China-U.S. Trade War Good Articles to Share
6. BJLAND 还是过渡低估,虽然外围股市动荡,对该股的影响甚微,会震掉一些惊弓之鸟。 Articles for investors
7. 八(發)第三周,马股指数终于有起色了?by 投资有理 投资有理·于你
8. Trump will be blamed for a global recession if he continues his trade war with China, says Boris Johnson Good Articles to Share
Partners & Brokers